Translational Molecular Imaging & Therapy
Modern medicine is facing the challenge to apply minimally invasive treatment strategies that suit the needs of the individual patient. This concept, entitled precision medicine, aims to improve patient care by stratifying patients into sub-groups that can be managed with tailored treatment plans. Due to its unique possibility to characterise the molecular fingerprint of disease via non-invasive imaging techniques, nuclear medicine plays an essential role in this stratification process. Not only can disease-specific imaging help to non-invasively define the molecular features of a disease, in doing so, but it can also make the field of nuclear medicine rise above and beyond its diagnostic role and allow image-guided therapy delivery. One can even argue that well established nuclear medicine topics such as “molecular imaging, isotope-based therapy, image-guided therapy, and theranostics” are instrumental for the realisation of precision medicine within the European healthcare system.
The success of nuclear medicine within Europe is dependent on its three pillars:
1) clinical implementation of available nuclear medicine technologies,
2) development of innovative nuclear medicine technologies and
3) translating new developments from the preclinical environment into the clinic.
It is in the latter two where the EANM Translational Molecular Imaging & Therapy (TMI&T) Committee can provide value, by connecting innovations with clinical needs and vice versa.
The TMI&T team has a highly multidisciplinary nature and features team members that have been active in developing new technologies able to translate preclinical concepts toward the clinic. Their expertise covers the translation of both chemical and technical developments focussed on the diagnosis and/or therapy for a range of clinical indications. The committee members are enthusiastic scientists with a background in the four key disciplines of chemistry, engineering, biology and medicine. Combined, the team 1) has unique positioning both in the clinical demand as well as the technical innovations in precision imaging, 2) highlights and actively promotes translational successes in the EANM community, 3) facilitates the training of future research/healthcare professionals in all translational disciplines, and 4) helps establish a strong translational pipeline through which new innovations can reach the clinic. The impact of these efforts is, amongst others, underscored by the success of the TMI&T organised tracks at the annual congress.
Committee aim: Provide a basis of knowledge and guidance to the nuclear medicine community in the context of translational science. Facilitate interaction between the clinical and technical, basic science-oriented EANM committees. As an interface towards external key players, the TMI&T Committee facilitates coordination, organisation, professionalisation between all involved parties, including sister-scientific societies, industry and national bodies.
For further insight into the TMI&T activities and vision, click here.
|Chair||Fijs Van Leeuwen (Netherlands)|
|Vice Chair||Margret Schottelius (Switzerland)|
|Secretary||Felix Mottaghy (Germany)|
|Scientific Programme Representative||Margret Schottelius (Switzerland)|
|Guideline Representative||Pedro Fragoso-Costa (Germany)|
|ESMIT Representative||Chiara Maria Grana (Italy)|
|Communication, Press & PR Representative||Latifa Rbah-Vidal (France)|
|Website Representative||Pedro Fragoso-Costa (Germany)|
|Member||Jean Pierre Pouget (France)|
|Member||Sergi Vidal Sicart (Spain)|
|Observer||Jan Grimm (United States of America)|
The Executive Office is the referral centre to which questions and requests of any kind may be addressed. The Office answers these directly where applicable or passes them on to the relevant EANM officer.
EANM Executive Office
Tel: +43 1 890 44 27
Fax: +43 1 890 44 27-9